Delivery Order SPE2DB20D1100-SPE2DB25FD8N6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,545.00 to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 110 MCG 12GM inhalers. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 4, 2025. The pharmaceutical products will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and primary distribution operations. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers, with a contract value of $24,494.88 and an ultimate completion date of July 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued as a competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive...
- The Defense Logistics Agency awarded a delivery order valued at $42,827.06 to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 110 microgram inhalers (12-gram units) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order represents a non-set-aside award issued under competitive procedures. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $1,498.25 to AmerisourceBergen Drug Corp for the supply of Fluticasone Propionate HFA 110 micrograms in a 12-gram inhaler. This firm fixed price contract, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,715.83 on July 29, 2025, for the supply of Fluticasone Propionate HFA 44 microgram inhalers (10.6 grams). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026. The product will be...
- The Defense Logistics Agency awarded a delivery order valued at $1,719.68 to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 44 micrograms in a 10.6-gram inhaler, with delivery performance required by August 6, 2025. This competitive award employs a firm fixed price model and represents a non-set-aside procurement executed on August 5, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $4,055.90 to AmerisourceBergen Drug Corp for the supply of Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 21, 2025, just three days after the award date of July 18, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a $2,083.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers. This non-set-aside contract was awarded on July 25, 2025, with an ultimate completion date of July 28, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs,...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Fluticasone Propionate HFA 110 MCG inhalers in 12-gram quantities. This competitively awarded, non-set-aside contract has a ceiling value of $1,108.08 with a firm fixed price and an ultimate completion date of August 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the primary contractor for this delivery order under its...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers, valued at $1,184.52, with an ultimate completion date of August 4, 2025. This is a competitively awarded, firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a prime pharmaceutical distributor and critical vendor for federal...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD8N6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,075.75 to AmerisourceBergen Drug Corp for Fluticasone Propionate HFA 110 micrograms in 12-gram inhalers. This non-set-aside contract was awarded on August 5, 2025, with an ultimate completion date of August 6, 2025, and operates under firm fixed price terms. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. This comprehensive pharmaceutical prime vendor contract enables AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The company's federal contract portfolio demonstrates its established capability to fulfill critical pharmaceutical procurement requirements through competitive federal contracting processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/5/25 |